Detecting Alzheimer’s disease years before the onset of dementia is becoming an increasingly realistic possibility thanks to advances in biomarkers and other diagnostic tools. This paradigm shift, which is transforming the way the disease is approached, was the focus of a forum held at the Senate that brought together experts, patient representatives, and policymakers. It included the participation of Dr. Mireia Tondo, a researcher at the Sant Pau Research Institute (IR Sant Pau).
The forum, organized by the Spanish Confederation of Alzheimer’s and Other Dementias (CEAFA), addressed the challenges associated with incorporating new tools capable of identifying biological alterations linked to the disease at very early stages. Participants analyzed how these advances are changing the diagnostic process and discussed the need to adapt healthcare systems to a reality in which Alzheimer’s disease can be detected long before the appearance of the most evident symptoms.
“We are witnessing a paradigm shift in the way Alzheimer’s disease is understood and diagnosed. We now have increasingly sensitive tools that allow us to detect biological alterations at very early stages, when there is still an important window of opportunity to intervene and plan patient care,” said Dr. Mireia Tondo. The IR Sant Pau researcher participated in a panel discussion focused on new biomarkers and their impact on the diagnosis and management of the disease.
During the forum, participants discussed how to ensure that scientific advances effectively reach patients. Experts highlighted the need to develop care pathways adapted to new diagnostic tools, strengthen coordination among healthcare professionals, and ensure equitable access to these technologies across the country.
Biomarkers are expected to play an increasingly significant role in the diagnosis of Alzheimer’s disease, as they make it possible to identify biological changes associated with the disease even before the appearance of the first cognitive symptoms. Their gradual incorporation into clinical practice presents significant opportunities, but also organizational, healthcare, and ethical challenges.
“The challenge is no longer simply having innovative diagnostic tools available, but ensuring that they can be incorporated effectively and equitably into healthcare systems. It is essential that scientific advances translate into real benefits for patients and their families,” added Dr. Tondo.
The forum also highlighted the importance of incorporating the perspectives of people affected by the disease and their caregivers into the design of future care models, as well as promoting greater coordination among research, clinical practice, and health policy.
The participation of the IR Sant Pau researcher in this forum reflects the institution’s longstanding commitment to studying the biological mechanisms of Alzheimer’s disease and developing new tools for its early detection.
Among the recent studies led by Sant Pau is a study published in the Journal of Lipid Research that identified an alteration in neuronal cholesterol uptake associated with the APOE4 genetic variant, the main genetic risk factor for Alzheimer’s disease. The study provided new evidence on the biological processes involved in the disease and opened new avenues for the development of future diagnostic and therapeutic strategies.
The forum held at the Senate highlighted how the emergence of increasingly precise biomarkers is driving a profound transformation in the approach to Alzheimer’s disease. Participants agreed that fully harnessing the potential of these advances will require close collaboration among researchers, healthcare professionals, patient associations, and policymakers. The goal is to translate scientific knowledge into meaningful improvements in the care of people affected by the disease.
